The evaluation efficacy of Desmopressin (1-deamino-8-D arginine Vasopressin) in increasing coagulation factor V and VIII in patients with combined factor V and VIII deficiency.

Aim of study: ٍEvaluation of possible usage of Desmopressin in treatment of the patients with combined factor V and VIII deficiency. Design of procedure of the study: Owing to combined factor V and VIII deficiency is rare disorder, all anciently recognized patients with 24 cases with combined factor V and VIII deficiency, were invited to accompanying in the study and after their agreements and signing informed consent forms and also applying inclusion and exclusion criteria, 20 cases were entered to the survey. At first, the patients were admitted to hematology department in hospital and a blood sample for determination of plasma levels of factor V and VIII was obtained and one hour after infusion of vasopressin, the second blood sample was obtained to determine possible elevation of coagulation factors V and VIII. The study method including: A) Population under study: 24 cases with combined factor V and VIII deficiency . Inclusion criteria: Confirmed affection with combined factor V and VIII deficiency using an identification card of hemophilia center or coagulation laboratory sheet showing diagnosis of combined factor V and VIII deficiency; Having more than 18 years old officially; Agreement to accompanying in research and signing informed consort form after auscultation details and process of blood sampling and blood volume; No infusion of factor VIII during last 48 hours; No infusion of fresh frozen plasma or cryopercipitate during last 48 hours; Not having active bleeding in time of accompanying in research; Exclusion criteria: Affection to other similar coagulation disorders, inter alia, combined factor VIII & IX deficiency; Having less than 18 years old officially; No agreement to accompanying in research and or signing informed consort form after auscultation details and process of blood sampling and blood volume; Infusion of factor VIII during last 48 hours; Infusion of fresh frozen plasma or cyopercipitate during last 48 hours; Having active bleeding in time of accompanying in research; Sample size: 24 cases that after applying inclusion and exclusion criteria, 20 cases entered the study. Intervention: Infusion of 0.4 microgram/Kg of Desmopressin Acetat (1-deamino-8-D arginine Vasopressin) using 50 CC of normal saline 0.9% by intravenous route. Time of intervention: After sampling first blood sample. Primary outcome or studied outcomes: Possible elevation of coagulation factors V and VIII in one hour after Desmopressin. The current study was designed as before & after method. At first the levels of coagulation factors V and VIII will be measured then Desmopressin drug will be infused and after passing an hour the levels of factors V and VIII will be assayed to determine their possible effects.

The financial expenses of current research was covered by vice chancellor for research in Mashhad University of Medical Sciences and Kedrion Company devoted needed drug free of charge to researchers.